XELJANZ®

FDA Approves Once-Daily Rheumatoid Arthritis Oral Drug, Xeljanz XR, by Pfizer
Pfizer, Inc., recently announced that the U.S. Food and Drug Administration (FDA) has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets as a once-daily treatment of patients with moderate to severe rheumatoid arthritis (RA) who ... [...]
6
Like
Save
Short on label expansions, Pfizer nabs FDA OK for new, once-daily Xeljanz
But in the meantime, it's rolling out a new extended-release formula for the disease it's already approved to treat. Wednesday, the FDA approved an extended-release formulation of Xeljanz, a second-line, oral rheumatoid arthritis therapy. Patients can ... [...]
4
Like
Save
FDA Approves Extended-Release Tofacitinib (Xeljanz XR) for Rheumatoid Arthritis
The FDA has given the green light to extended-release tofacitinib citrate tablets (Xeljanz XR, Pfizer) for the once-daily treatment of moderate-to-severe rheumatoid arthritis (RA) in patients who have had an inadequate response to or are intolerant of ... [...]
6
Like
Save